Tag:
MannKind
Latest Headlines
Latest Headlines
MannKind starts Phase II melanoma vax trial
MannKind is best known in the industry for its ongoing attempts to win approval of it's inhaled insulin drug Afrezza. The developer is waiting for a final FDA decision on the drug later this year,
MannKind wins two Facility of the Year awards
NEW YORK - MannKind ( NASDAQ: MNKD ) will be strutting the aisles of Interphex this week, chest out, a smile on its corporate face. The company is a double winner in the 2010 Facility of the Year
